SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

BREA is trending as traders discuss its potential as a crypto treasury play following news of a $300M private placement, with community members comparing it to previous runners like $QMMM. Bullish sentiment is fueled by the company's plans to rebrand as Solmate and focus on Solana-based digital assets, while others caution about potential dilution and the sustainability of the rally. The stock's low float and volatile price action are also driving considerable conversation.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx ($FDX) is trending following its Q1 earnings release, which featured a better-than-expected EPS and revenue. Despite the earnings beat, the stock dipped in after-hours trading as community members discuss the company's soft guidance and concerns around global trade and tariffs. Some traders are speculating about a potential short squeeze and monitoring the upcoming conference call for further insights.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Disney is trending amid discussions around free speech and potential boycotts related to the removal of Jimmy Kimmel's show, sparking debates over political polarization and censorship. The community is divided, with some supporting Disney's decision and others criticizing it as an attack on free speech. Broader conversations include the company's financial performance, streaming strategy, and the impact of political stances on its brand.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Lennar Corp. is trending as investors closely monitor upcoming earnings and anticipate potential impacts from housing market dynamics and interest rate fluctuations. Community discussions revolve around whether Lennar can maintain margins amid affordability challenges and if the Millrose spin-off will affect the stock's performance. Analysts have mixed views, with some lowering price targets while others remain optimistic about Lennar's strategic positioning.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors weigh the potential impact of FedEx's earnings and broader concerns about shipping volumes and costs. Community discussions revolve around the stock's high dividend yield and whether it can be sustained, along with speculation about a potential bottom and future price targets. Some traders are also discussing the impact of US-China trade tensions on shipping demand for UPS.

༼ つ ◕_◕ ༽つ gib is a meme coin on Hedera, inspired by the classic copy pasta meme of persistence and community. Born from the viral 2013 Dota 2 Diretide event, gib embodies the power of collective action. As one of the first ASCII-named tokens on-chain, gib merges meme culture with blockchain innovation, helping users explore Hedera, crypto, and tech in a fun, engaging way. ༼ つ ◕_◕ ༽つ gib knowledge

GIB.X is trending as a meme coin on the Hedera network, drawing comparisons to PENGU and DOGE, with the community highlighting its small market cap and potential for significant growth. Many community members emphasize GIB's strong community, meme potential, and the backing of the Hedera Foundation as reasons for its bullish sentiment. The coin is also being discussed in the context of the broader Hedera (HBAR) ecosystem, with some seeing it as a gateway for new users.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amid discussions around Panasonic's anode-free solid-state battery announcement, with investors speculating about a potential partnership with QS and Tesla. The community is analyzing patent landscapes and commercialization timelines, debating whether this signals validation or competition for QS's technology. Bullish sentiment suggests a possible breakthrough for solid-state batteries, while bears caution about execution risks and insider selling.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as the community anticipates upcoming earnings, with discussions focused on revenue growth, potential profitability, and long-term prospects. Community members speculate on potential buyout or partnership news, particularly regarding Regeneron, while praising the company's technology and market position. Bullish sentiment is fueled by positive financial outlook and confidence in the company's pipeline.

Darden Restaurants, Inc. is a full-service restaurant company, which engages in the provision of restaurant services. It operates through the following segments: Olive Garden, LongHorn Steakhouse, Fine Dining, and Other Business. The Olive Garden segment is the largest full-service dining Italian restaurant operator. The LongHorn Steakhouse segment includes the results of the company-owned LongHorn Steakhouse restaurants. The Fine Dining segment consists of the premium brands that operate within the fine-dining sub-segment of full-service dining and includes the results of its company-owned The Capital Grille and Eddie V's restaurants. The Other Business segment aggregates the remaining brands and includes the results of its company-owned Cheddar's Scratch Kitchen, Yard House, Seasons 52 and Bahama Breeze restaurants, and from franchises and consumer-packaged goods sales. The company was founded by William B. Darden in 1938 and is headquartered in Orlando, FL.

Darden Restaurants, Inc.

Darden Restaurants ($DRI) is trending amid mixed reactions to recent earnings and revenue figures, with some analysts anticipating price target increases. Community discussions highlight momentum traders observing strong tape action and potential range expansion, while others focus on short positions around a key price level. The broader context includes potential catalysts from clean tech initiatives and utility pilot markets.

Wormhole is a cross-chain messaging protocol that enables secure transfers of data or tokens across different blockchain networks. It supports a variety of applications, including DeFi, NFTs, and governance, by allowing data to be moved between blockchains efficiently and securely. Wormhole employs multiple verification methods to ensure the integrity and validity of the data transmitted through its network.

Wormhole

Wormhole ($W.X) is trending as discussions around its cross-chain interoperability heat up, particularly its integration with Ripple and potential to unlock significant cross-chain potential. Community members are actively discussing its updated "W 2.0 Tokenomics" and speculating on price targets, drawing comparisons to other successful crypto projects. The focus remains on Wormhole's role as a 'universal translator' aiming to connect various blockchains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The U.S. Food and Drug Administration has sent a letter to Novo Nordisk (NVO) CEO Maziar Mike Doustdar regarding the company’s promotional communication featuring Oprah Winfrey, alleging that the video is false or misleading.The video originally appeared on ABC as a Primetime Oprah Special on March 18, 2024. It also subsequently appeared on Hulu. The video is a 42-minute special program hosted by Oprah Winfrey, featuring patient testimonials from individuals who struggle with obesity and excessive weight, including those who have used Novo’s Wegovy, Ozempic, or Victoza.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-716495-09092025">alleged</a> in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. The video was also not submitted at the time of initial dissemination or publication as required by law, the agency said.“These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the safety of Wegovy, Ozempic, and Victoza, which are drugs with multiple serious, potentially life-threatening risks,” the agency said.The FDA also noted that obesity and type 2 diabetes are significant public health concerns in the U.S., and consumers who seek medical treatment for these conditions should receive truthful and nonmisleading information regarding the serious risks associated with the use of the drugs. While Novo’s Wegovy is used for weight management, its Ozempic and Victoza are used to treat type 2 diabetes.The FDA said that several advisory comments dated as long back as 2010 addressed draft promotional communications for Victoza with certain similarities to the aforementioned video. The agency expressed concerns that <a href="https://stocktwits.com/symbol/NVO">Novo</a> is promoting the three drugs in a manner that fails to present the serious risks of these drug products in a truthful and nonmisleading manner, despite the FDA’s prior comments.While the video includes numerous representations of the benefits of Wegovy, Ozempic, and Victoza made by representatives of Novo Nordisk, it omits important risk information or minimizes the risks associated with these drug products, the FDA said. Only four minutes in total were devoted to the important risks associated with GLP-1 drugs, such as Wegovy, the FDA said.The video also omits reference to how the drugs are contraindicated in patients with a personal or family history of Medullary Thyroid Cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2, it added. The omissions are exacerbated by statements from Amanda Velazquez, a paid consultant of Novo, made on the video, the FDA said.NVO stock is down by 33% this year and by 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-tumbles-7-percent-after-fda-letter/chwyNFWRdzV">Hims &amp; Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’ 

The FDA alleged in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. 

Equity

The FDA alleged in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. 


Novo Nordisk (NVO) announced on Tuesday that its new obesity treatment, Cagrilintide, reduced body weight by 11.8% after 68 weeks in a late-stage study.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916427">reported</a> an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in the trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy, plus lifestyle intervention, for adults with obesity or overweight and a weight-related comorbidity without diabetes. The above levels of weight reduction were observed in participants who adhered to the treatment. Regardless of adherence, average weight loss with Cagrilintide was 11.5% compared to 3.0% with placebo after 68 weeks.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:575/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_9_59_21_AM_png_2efadb4b5b.webp" alt="NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="575" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment that the stock rallied only 2-3% on good news.<stembedurl>https://stocktwits.com/King990/message/628811943</stembedurl>Cagrilintide works differently from currently approved GLP-1-based treatments for weight loss, including Novo’s Wegovy and Eli Lilly’s Zepbound. The new drug mimics the naturally occurring hormone amylin that helps control blood glucose levels and appetite by slowing gastric emptying, reducing glucagon secretion, and promoting satiety.The company also stated that approximately one in three participants receiving Cagrilintide achieved 15% or more weight loss, compared to approximately one in 20 participants receiving a placebo, when patients adhered to the treatment.Novo stated that the drug was well-tolerated, while adding that the most common side effects were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation. These side effects were mainly temporary and mild to moderate, and 1% of participants discontinued the study due to nausea, compared to 0.1% of participants who received a placebo.“We’re excited that these data, the first phase 3 data of a next-generation amylin therapy, show promise, and we look forward to further investigating cagrilintide’s potential in the dedicated phase 3 RENEW programme,” said Martin Holst Lange, chief scientific officer and executive vice president of Research and Development at Novo Nordisk.Another late-stage programme investigating the efficacy and safety of Cagrilintide in people with obesity or overweight is due to start in the fourth quarter of this year.Separately, Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://bloomberg.com/news/articles/2025-09-16/novo-plans-to-seek-us-approval-for-its-high-dose-obesity-shot?sref&amp;#61;8QBk7toa">reported</a> on Tuesday that Novo plans to seek U.S. regulatory approval for a high-dose version of Wegovy. Though the drugmaker hasn’t yet formally announced its U.S. plans, it intends to file for the U.S. Food and Drug Administration approval, said Lange at the European Association for the Study of Diabetes conference in Vienna, according to the report.NVO stock is down 34% this year and by about 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-opens-probe-into-174000-plus-tesla-model-y-vehicles/chwyiNgRdz5">US Regulator Opens Probe Into 174,000-Plus Tesla Model Y Vehicles – Check Out Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-Stage Study

The company reported an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in a trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy. 

Automaker Stellantis NV (STLA) is recalling 53,849 vehicles in the U.S. over concerns that the fuel pump may fail, U.S. auto safety regulator National Highway Traffic Safety Administration (NHTSA) said on Tuesday.The NHTSA <a target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/rcl/2025/RCLRPT-25V586-8785.pdf">noted</a> that a fuel pump failure can result in a loss of fuel flow and drive power, increasing the risk of a crash. The recall includes model year 2017-2019 Alfa Romeo Giulia and model year 2018-2019 Alfa Romeo Stelvio vehicles. Some of the vehicles may have been built with a fuel delivery module (FDM) that contains internal components susceptible to heat, resulting in a loss of flow rate and, consequently, a reduction in motive power, it said. &nbsp;The remedy for the issue is currently under development. While letters notifying vehicle owners of the safety risk are expected to be mailed by the end of October, letters regarding the remedy will be sent once it becomes available, it added.The NHTSA noted that the recall follows an investigation initiated in January 2024. Stellantis has identified 437 customer complaints and field reports in North America that are potentially related to the issue. The company is also aware of five crashes and three injuries potentially related to the issue across all markets, it said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">STLA stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:580/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_7_09_28_AM_png_0b39e79559.webp" alt="STLA's Sentiment Meter and Message Volume as of 7:09 a.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="580" height="59"><figcaption>STLA's Sentiment Meter and Message Volume as of 7:09 a.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed hopes for a rally this week, with the stock touching $10.<stembedurl>https://stocktwits.com/BullRunx100/message/628744748</stembedurl>STLA stock is down by about 26% this year and by about 37% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bloom-energy-stock-jumped-7-this-morning/chwyhXlRdyC">Bloom Energy Stock Jumped 7% This Morning – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stellantis Recalls Nearly 54,000 Vehicles In US Over Concerns Regarding Fuel Pump: But Retail Sees Stock Rallying To $10 This Week

The recall includes model year 2017-2019 Alfa Romeo Giulia and model year 2018-2019 Alfa Romeo Stelvio vehicles.

Eli Lilly (LLY) and Novo Nordisk (NVO) are reportedly expected to launch oral obesity pills by next year once they get regulatory approval in the U.S.According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. Daily pills would likely bring GLP-1s to more people, the report stated.&nbsp;The report noted that the primary aim of the study is to assess the effectiveness of the pills in lowering blood sugar levels in individuals with Type 2 diabetes, while also monitoring their impact on weight loss.“We wouldn’t have undertaken this head-to-head phase three randomized control trial unless we had a lot of confidence that orforglipron would fare well in comparison to oral semaglutide,” Skovronsky told CNBC.Retail sentiment on <a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> remained unchanged in the ‘neutral’ territory, with message volumes at ‘low’ levels, according to Stocktwits data.The report said that Skovronsky noted the results across trials, which did not directly compare the two drugs, should not be made, given Novo’s pill appears more effective with fewer discontinuations.&nbsp;Meanwhile, Novo’s Chief Scientific Officer, Martin Holst Lange, told CNBC in another interview that the data speaks for itself.Retail sentiment on <a href="https://stocktwits.com/symbol/NVO">Novo</a> remained in the ‘bearish’ territory, with chatter at ‘low’ levels, according to data from Stocktwits.The report explained that Novo’s upcoming obesity pill is a tablet form of its weekly injection, Wegovy. In contrast, Lilly’s pill, Orforglipron, is a completely new drug and different from its injectable treatment, Zepbound. According to Skovronsky, Zepbound remains the benchmark for effectiveness, helping patients lose over 20% of their body weight.The CNBC report noted that neither Novo’s pill nor Lilly’s oral drug is as effective as Zepbound. It added that Orforglipron&nbsp;has achieved around 12% weight loss at its highest dose, while oral Semaglutide&nbsp;has reached about 17%, prompting uncertainty over how many patients will choose a pill if it delivers less weight loss than injectable options.Skovronsky told CNBC that pills could eventually become the primary way that obesity would be treated, and that oral drugs could have a larger market share than shots.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rh-stock-sees-slew-price-target-cuts-from-wall-street-as-trump-tariffs-bite/chw8MrGRdDN">RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite</a>

While Lilly’s broader portfolio spans diabetes, cancer, and neuroscience treatments, investors remain largely focused on Mounjaro and Zepbound. 

Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company expects trial results within months from a direct comparison between its oral drug Orforglipron and Novo Nordisk’s Semaglutide.

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. 

Japanese carmaker Toyota Motor (TM) announced on Thursday that it is conducting a voluntary safety recall of approximately 591,000 vehicles in the U.S. due to concerns regarding the instrument panel.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://pressroom.toyota.com/toyota-recalls-certain-toyota-and-lexus-vehicles-5/">recall </a>involves certain Toyota Venza, Crown, Crown Signia, RAV4, GR Corolla, 4Runner, Camry, Grand Highlander, Tacoma, Highlander, and certain Lexus LS, RX, and TX vehicles.The 12.3-inch display on the instrument panel may be blank at startup, reducing the ability to see certain malfunction indicators and increasing the risk of a crash, the company stated.As for a fix, Toyota and Lexus dealers will inspect the vehicle and replace parts if needed, the company said, while adding that it will inform customers by mid-November.NYSE-listed shares of Toyota traded flat at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TM">TM stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.This year, through the end of July, Toyota sold nearly 6.1 million Toyota and Lexus brand vehicles worldwide. Sales in the U.S., including Hawaii, during the period were almost 1.5 million vehicles, surpassing any other single market and marking a 6.3% year-over-year growth. In Japan, the company’s home country, the company sold only 903,694 vehicles.However, the company produced only 800,178 vehicles in the U.S. during the period, while over 1.9 million were made in Japan. Earlier this week, it was <a href="https://stocktwits.com/news-articles/equity/markets/toyota-reshapes-us-operations-under-tariff-pressure-ev-su-vs-coming-to-kentucky-lexus-es-shifts-to-japan/chwNbuKRdHb">reported</a> that Toyota plans to produce two new three-row battery electric SUVs at its Kentucky plant as part of a strategy to streamline its U.S. operations. The changes follow the Trump administration's imposition of a 25% tariff on imported cars in April—a significant increase from the previous 2.5% rate. Following negotiations, a separate agreement reduced the rate to 15% for Japanese vehicles and parts.TM stock is up 2% this year and approximately 13% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/applied-digital-stock-advances-on-ai-optimism-retail-momentum-builds/chwNo3dRdvH">Applied Digital Stock Advances On AI Optimism, Retail Momentum Builds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Raindrops are seen on Toyota car logo in Krakow, Poland on December 23, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Toyota Recalls Over Half A Million Vehicles In The US

The 12.3-inch display on the instrument panel may be blank at startup, which increases the risk of a crash, the company stated.

Magna International (MGA) said on Thursday that Philip D. Fracassa will succeed Patrick McCann as Executive Vice-President and Chief Financial Officer (CFO) of the company, effective immediately.McCann will step down from the company after a career spanning more than 26 years with Magna, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/11/3148417/0/en/Magna-Names-Philip-D-Fracassa-Chief-Financial-Officer.html">said</a>, while adding that the outgoing executive will remain in an advisory role until the end of February to enable a smooth transition.Fracassa previously served as Executive Vice President and CFO of The Timken Company since 2014, Magna said, adding that he brings extensive experience in the automotive and industrial sectors. He was also previously employed at automaker General Motors.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MGA">MGA stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1364/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_9_07_06_AM_png_5286b70d90.webp" alt="MGA's Sentiment Meter and Message Volume as of 9:07 a.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="1364" height="122"><figcaption>MGA's Sentiment Meter and Message Volume as of 9:07 a.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>Fracassa’s appointment will be instrumental as the company delivers on its full-year outlook, the company said. Magna updated its full-year outlook in August and now expects total sales to be between $40.4 billion and $42 billion, and adjusted net income to be between $1.35 billion and $1.55 billion.In the second quarter, the company’s sales decreased 3% to $10.6 billion, as light vehicle production declined by 6% and 2% in North America and Europe, respectively. Adjusted and diluted earnings per share, however, rose 7% in the quarter to $1.44.Magna, the auto parts supplier, has about 164,000 employees across 338 manufacturing operations and 106 product development, engineering, and sales centres. The company’s results are dependent on light vehicle production by its customers, including Ford, GM, and Stellantis, in three key regions: North America, Europe, and China.Shares of the company rose 10% this year and by about 17% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/maze-therapeutics-stock-soars-after-150-million-private-placement/chwN1StRdvX">Maze Therapeutics Stock Just Shot Up 56% Pre-Market Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Magna International logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ford Supplier Magna International Appoints Former Timken Executive As CFO

Philip D. Fracassa will succeed Patrick McCann, who will step down after a career spanning more than 26 years with Magna. 

The U.S. auto safety regulator, the National Highway Traffic Safety Administration (NHTSA), announced on Monday that it has opened an investigation into 287,000 Chrysler Pacifica vehicles due to concerns about intermittent loss of electric power steering (EPS) during gradual turns.The probe includes model year 2017-2018 Pacifica minivans, including some plug-in hybrids. The NHTSA <a target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2025/INOA-PE25009-18789.pdf">said</a> that its Office of Defects Investigation (ODI) opened the probe to assess the scope, frequency, and potential safety consequences of alleged defects related to the EPS system.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">Stellantis stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of the company traded 2% lower at the time of writing.<figure class="image"><img style="aspect-ratio:573/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_10_32_39_AM_png_1093ce31f5.webp" alt="STLA's Sentiment Meter and Message Volume as of 10:32 a.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="573" height="62"><figcaption>STLA's Sentiment Meter and Message Volume as of 10:32 a.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user noted that the stock is “getting blasted” once again.<stembedurl>https://stocktwits.com/AanoldMcFace/message/627823094</stembedurl>The regulator said that ODI received 94 reports of a condition in which the steering system exhibits a sticking sensation during gradual turns, particularly when the steering wheel is positioned near the 11 o'clock or 1 o'clock position. During these events, increased steering effort is required to return the wheel to the center, the complainants alleged. Some also noted that this is followed by a sudden reactivation of EPS assistance, which may result in an oversteer condition.This behavior of the electric power steering could increase the risk of a crash, particularly at higher speeds, the NHTSA noted. However, the regulator is not aware of any crashes, fires, or injury incidents related to the alleged complaint.STLA stock is down 32% this year and about 43% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-biontech-updated-covid-vaccine-shows-robust-immune-response-in-late-stage-study/chwW6azRdrB">Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

2017 Chrysler Pacifica is seen on Saturday, January 14, 2017. Staff photo by Christopher Evans (Photo by Christopher Evans/MediaNews Group/Boston Herald via Getty Images)

Stellantis Stock Slips After US Regulator Probes 287,000 Chrysler Minivans Over Concerns Regarding Electric Power Steer

The NHTSA stated that its Office of Defects Investigation (ODI) initiated an investigation to assess the scope, frequency, and potential safety implications of alleged defects related to the EPS system. 

Sanofi (SNY) announced on Thursday that its experimental drug, Amlitelimab, met all primary and key secondary endpoints in a late-stage study in adults and adolescents with atopic dermatitis (AD).The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-09-04-05-00-00-3144170">study</a> enrolled 601 adults and adolescents aged 12 years and older with moderate-to-severe AD. Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at week 24. Furthermore, a progressive increase in efficacy was observed during the treatment period in patients who were dosed every four weeks as well as in those who were dosed every 12 weeks, the company said.The most common treatment-emergent adverse events, such as upper respiratory tract infection, were more common in the placebo arm compared to the Amlitelimab-treated arms of the study, it said.Shares of the company, however, traded 9% lower in the premarket session at the time of writing.According to a Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-sheds-13-billion-value-weak-trial-results-eczema-drug-2025-09-04/">report</a>, Jefferies analysts opined that the trial results fell short of those from an earlier trial and of rival biologic drugs. However, the drug's safety profile and convenient 12-week dosing regimen could still support its use.JPMorgan, meanwhile, noted that the data confirmed that Amlitelimab is less effective than Sanofi’s approved drug Dupixent, Reuters added. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_7_50_44_AM_png_2f5aa98d10.webp" alt="SNY's Sentiment Meter and Message Volume as of 7:51 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="578" height="61"><figcaption>SNY's Sentiment Meter and Message Volume as of 7:51 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure>Sanofi’s Dupixent is approved to treat atopic dermatitis in addition to asthma, chronic spontaneous urticaria, and other diseases. In the second quarter, Dupixent sales increased by 21.1% to €3.8 billion ($4.43 billion), and the company was expecting Amlitelimab to complement the blockbuster drug.The firm now looks forward to sharing additional late-stage results from the clinical development program of Amlitelimab in atopic dermatitis, said Houman Ashrafian, Executive Vice President, Head of Research &amp; Development at Sanofi.SNY stock is up 3% this year but down approximately 15% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/fda-says-no-advisory-commitee-meeting-required-for-aquestive-oral-epinephrine-film/chwd20pRdYB">FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: €1= $1.17

Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More

Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at week 24, the company said. 

Citi on Friday lowered its price target on Chinese EV maker Li Auto (LI) to $25.60 from $33.90 while keeping a ‘Neutral’ rating on the shares.The new price target still represents a 10% upside to the stock’s closing price on Thursday. Citi cut estimates to reflect Li's third-quarter (Q3) outlook missing expectations, as per TheFly. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LI">Li stock</a> jumped from ‘Neutral’ to ‘Bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_29_at_7_08_31_AM_png_e74a0ea2fe.webp" alt="LI's Sentiment Meter and Message Volume as of 7:08 a.m. ET on Aug. 29, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>LI's Sentiment Meter and Message Volume as of 7:08 a.m. ET on Aug. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user stated that they expect the shares ‘to eventually implode.’<stembedurl>https://stocktwits.com/QCExpert/message/626951407</stembedurl>On Thursday, Li Auto stated that it expects third-quarter (Q3) vehicle deliveries to be between 90,000 and 95,000 vehicles, representing a year-over-year decrease of 41.1% to 37.8%. Li Auto delivered 30,731 vehicles in July, and the new third-quarter outlook suggests that the company expects to deliver a similar number of vehicles in the next two months, despite the introduction of new products.Total revenue is also expected to decrease by 42.1% to 38.8% in the quarter, ranging from RMB 24.8 billion ($3.5 billion) to RMB 26.2 billion, below the estimated RMB 26.26 billion. For the second quarter through the end of June, the company reported total revenues of RMB 30.2 billion, below the analyst estimate of RMB 31.82 billion.Adjusted and diluted net earnings per American depositary share (ADS) attributable to ordinary shareholders were RMB 1.37 in the second quarter, lower than an estimated RMB 1.73.LI stock is down 3% this year but up approximately 18% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/de-minimis-ends-today-heres-whos-likely-to-win-and-lose-after-us-tariff-shift/chtThciRdNB">De Minimis Ends Today – Here’s Who’s Likely To Win And Lose After US Tariff Shift</a>For updates and corrections, email newsroom[at]stocktwits[dot]comExchange Rate: RMB1= $0.14

People stop by the booth of the Chinese carmaker Li Auto during an auto show in Hangzhou. (Photo credit should read LONG WEI / Feature China/Future Publishing via Getty Images)

Citi Lowers Price Target On This Chinese EV Maker After Disappointing Q3 Guidance: Retail Expects Shares To ‘Eventually Implode’

Citi’s new price target still represents a 10% upside to the stock’s closing price on Thursday.

NYSE-listed shares of Alibaba jumped 4% higher in the pre-market session on Friday, despite the company reporting earnings for the June quarter below Wall Street expectations.The company reported revenue of RMB 247.652 billion ($34.62 billion), marking a 2% year-on-year increase, which was below the estimated RMB 253.808 billion. Adjusted and diluted earnings per American depository share came in at RMB 14.75, marking a drop of 10% year-on-year.Revenue from the company’s cloud intelligence group, however, &nbsp;jumped 26%, while revenue from its core China E-commerce Group rose 10%.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BABA">BABA stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory, while message volume improved from ‘high’ to ‘extremely high’ levels.Net income for the June quarter rose 78% to RMB 43.12 billion. The rise is attributable to the gain from the disposal of the local consumer service business of Turkish e-commerce platform Trendyol, which was partially offset by a 3% decrease in income from operations.Alibaba <a target="_blank" rel="noopener noreferrer nofollow" href="https://data.alibabagroup.com/ecms-files/1532295521/d09dd487-1a87-4e17-aa5d-9eb4da7eb56b/Alibaba%20Group%20Announces%20June%20Quarter%202025%20Results.pdf">stated</a> that revenue from its Cloud Intelligence segment totalled RMB 33.40 billion, driven by public cloud revenue growth, including the increasing adoption of AI-related products.AI-related product revenue maintained triple-digit year-over-year growth for the eighth consecutive quarter, the company stated, while adding that it is seeing increased demand for compute, storage, and other public cloud services to support AI adoption. Earnings before interest, taxes, depreciation, and amortization (EBITDA) from the segment also rose 26% to RMB 2.95 billion.“Driven by robust AI demand, Cloud Intelligence Group experienced accelerated revenue growth, and AI-related product revenue is now a significant portion of revenue from external customers. Looking ahead, we remain committed to investing in our two strategic pillars of consumption and AI + Cloud to capture historic opportunities and drive long-term growth,” said CEO Eddie Wu.The company’s total revenue from Alibaba China E-commerce Group rose 10% to RMB 140.07 billion, while EBITDA fell 21% to RMB 38.40 billion.BABA stock gained 41% this year and by 48% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/de-minimis-ends-today-heres-whos-likely-to-win-and-lose-after-us-tariff-shift/chtThciRdNB">De Minimis Ends Today – Here’s Who’s Likely To Win And Lose After US Tariff Shift</a>For updates and corrections, email newsroom[at]stocktwits[dot]comExchange Rate: RMB1= $0.14

2025/07/18: The "Alibaba" logo on a blue background at the 3rd China International Supply Chain Expo. 

BABA Stock Rises Pre-Market On Revenue Growth In Cloud Intelligence, China E-commerce Segments

Adjusted and diluted earnings per American depository share in the second quarter came in at RMB 14.75, marking a drop of 10% year-on-year.

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

DFAX
Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DFAX News

DFAX Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF